Immunological aspects of pediatric cancer and immunotherapy Book Section
| Authors: | Park, J. A.; Cheung, N. K. V. |
| Editors: | Losty, P. D.; La Quaglia, M.; Sarnacki, S.; Fuchs, J.; Taguchi, T. |
| Article/Chapter Title: | Immunological aspects of pediatric cancer and immunotherapy |
| Abstract: | Overall survival rates for pediatric cancers exceeded 80%. Yet, these statistics have been stagnant for more than three decades despite the considerable medical advances in chemotherapeutics, radiotherapies, surgical treatment, stem cell transplantation, and small molecule-targeted therapies. In particular, high-risk diseases, including metastatic neuroblastomas, still have dismal outcomes, where long-term patient survival is less than 50%. Although cancer immunotherapeutics including monoclonal antibodies (mAbs) and T-cell-based immunotherapies have emerged as major breakthroughs, most of the successes have been confined to hematologic malignancies or adult cancers, and the progress has been slow in pediatrics. Of note, the success of GD2 targeted immunotherapy in high-risk neuroblastomas seems remarkable. Here, we outline the immunologic characteristics of pediatric neuroblastomas and update the current state of the art in the clinic, while summarizing the promising and novel immunotherapeutic approaches ready for translation to the bedside. © 2022 Taylor & Francis Group, LLC. |
| Book Title: | Pediatric Surgical Oncology |
| ISBN: | 978-0-8153-4870-2 |
| Publisher: | CRC Press |
| Publication Place: | Boca Raton, FL |
| Date Published: | 2022-01-01 |
| Start Page: | 23 |
| End Page: | 28 |
| Language: | English |
| DOI: | 10.1201/9781351166126-6 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Book chapter: 6 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
-
411La Quaglia -
648Cheung -
19Park
Related MSK Work